PTAB Finds Favor In Court; Novartis Is Latest To Strike Out In Challenge

Federal Circuit affirms US Patent Trial and Appeal Board decision against Gilenya composition patent a week after upholding board decision on Exelon Patch patents; court has reviewed 200 PTAB decisions and affirmed 158 of them.

Court of Appeals for Federal Circuit Lafayette Park Across from White House Washington DC
Court of Appeals for Federal Circuit

Novartis AG's experience battling inter partes review (IPR) patent challenges shows how perilous the process is for patent owners. The risk was reinforced this month as the US Court of Appeals for the Federal Circuit upheld decisions invalidating patents on two Novartis drugs.

In an April 12 opinion, the court affirmed the US Patent and Trademark Office's Patent Trial and Appeal Board decision that a composition patent covering its multiple sclerosis pill Gilenya (fingolimod) is invalid for being obvious. A week earlier, the Federal Circuit upheld a PTAB decision invalidating two patents on its Exelon Patch (rivastigmine) for Alzheimer's disease

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legal & IP

More from Pink Sheet

US FDA Expands Surprise Foreign Inspections But Loses Associate Commissioner Michael Rogers

 
• By 

Commissioner Martin Makary’s repeated characterization of foreign facilities as being subject to lower standards than domestic counterparts may have contributed to Rogers’ decision to retire as head of the recently formed Office of Inspections and Investigations.

Sponsors Like START Rare Disease Pilot, Will Prasad Maintain Its Momentum?

 
• By 

Sponsors reported faster development times for products that joined the pilot program intended to speed rare disease treatments in CBER.

EU HTA Regulation: ‘Stepping Beyond’ JCAs May Be Needed For Very Rare Disease Drugs

 

Cooperation between health technology assessment bodies across the EU will lead to a better joint clinical assessment process over time, but patients cannot afford a lengthy wait for improvements, speakers at a cell & gene therapy conference said.